Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695 | 1.00 | MAPT (1.00) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL1542719 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL637069 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL20769805 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL9975142 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL8848607 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL29559044 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| Atovaquone SCHEMBL21694 | 0.90 | MAPT (0.82) | MAPTLMNAMEN1USP2TP53 | |
| SCHEMBL15083851 | 0.85 | MAPT (0.74) | MAPTLMNAMEN1USP2TP53 | |
| SCHEMBL28082527 | 0.85 | MAPT (0.73) | MAPTLMNAMEN1USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-4663240-A1 | IFN- PATHWAY INHIBITORS FOR USE IN THE TREATMENT OF FSHD | Ospedale San Raffaele S.r.l. (IT) | 2025-12-17 | — | — | EP | disclosed |
| US-20250177323-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | ELEVAID THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | LIFECEUTIX CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| US-12245994-B2 | Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammation | ELEVAID THERAPEUTICS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-12102605-B2 | Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammation | ELEVAID THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4431102-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | Lifeceutix Co., Ltd. (KR) | 2024-09-18 | — | — | EP | disclosed |
| US-20240293424-A1 | CARNITINE-PALMITOYL-TRANSFERASE-1 (CPT-1) INHIBITORS FOR USE IN A METHOD OF PREVENTING OR TREATING SEPSIS IN A MAMMALIAN SUBJECT | 2N PHARMA APS (DK) | 2024-09-05 | — | — | US | disclosed |
| US-20240245629-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR REDUCING STEROID USE, ALL-CAUSE HOSPITALIZATION, OR ADVANCED THERAPY USE IN A SUBJECT DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, OR ULCERATIVE COLITIS | ELEVAID THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-118317775-A | New combination medicine for treating coronavirus infection, pharmaceutical composition and application thereof | 南京强新生物医药有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100305087-A1 | ACTIVE PHARMACEUTICAL INGREDIENT ON A SOLID SUPPORT, AMORPHOUS AND WITH AN IMPROVED SOLUBILITY | LEK PHARMACEUTICALS D.D. (SI) | 2010-12-02 | — | — | US | disclosed |
| EP-2234602-A1 | ACTIVE PHARMACEUTICAL INGREDIENT ON A SOLID SUPPORT, AMORPHOUS AND WITH AN IMPROVED SOLUBILITY | LEK Pharmaceuticals d.d. (SI) | 2010-10-06 | — | — | EP | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| CN-101265171-B | Technique for synthesizing atovaquone | CHONGQING HALLOCHEM PHARMA CO LTD | 2010-06-02 | — | — | CN | disclosed |
| WO-2009080698-A1 | ACTIVE PHARMACEUTICAL INGREDIENT ON A SOLID SUPPORT, AMORPHOUS AND WITH AN IMPROVED SOLUBILITY | LEK PHARMACEUTICALS D.D. (SI) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072042-A1 | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility | Lek Pharmaceuticals D.D. (SI) | 2009-06-24 | — | — | EP | disclosed |
| CN-101265171-A | Technique for synthesizing atovaquone | CHONGQING HALLOCHEM PHARMA CO (CN) | 2008-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305087-A1 | ACTIVE PHARMACEUTICAL INGREDIENT ON A SOLID SUPPORT, AMORPHOUS AND WITH AN IMPROVED SOLUBILITY | TIA1, SOST, ABCG2 | MAPT 2670/4885LMNA 3718/4885MEN1 1822/4885 |
| US-20240293424-A1 | CARNITINE-PALMITOYL-TRANSFERASE-1 (CPT-1) INHIBITORS FOR USE IN A METHOD OF PREVENTING OR TREATING SEPSIS IN A MAMMALIAN SUBJECT | CPT1A, CPT1B, CPT2 | MAPT 914/4885LMNA 3332/4885MEN1 4556/4885 |
| US-20250177323-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | IL4I1, MPO, TPMT | MAPT 2698/4885LMNA 2912/4885MEN1 3469/4885 |
| US-20240245629-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR REDUCING STEROID USE, ALL-CAUSE HOSPITALIZATION, OR ADVANCED THERAPY USE IN A SUBJECT DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, OR ULCERATIVE COLITIS | TPMT, IL17A, IL4I1 | MAPT 3807/4885LMNA 3323/4885MEN1 3136/4885 |
| US-12102605-B2 | Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammation | IL4I1, MPO, TPMT | MAPT 2698/4885LMNA 2912/4885MEN1 3469/4885 |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | GLA, LIMS1, TP53 | MAPT 2871/4885LMNA 25/4885MEN1 2880/4885 |
| US-12245994-B2 | Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammation | IL4I1, MPO, TPMT | MAPT 2698/4885LMNA 2912/4885MEN1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.